- First stated window
- “in the second half of 2026”SEC Form 10-Q, filed
- Disclosure date
- None foundLast checked:
Timeline
How wording is compared
Equivalent half-year, quarter, and year notations are compared together while original wording stays visible. Qualifiers such as early, mid, late, and end remain distinct. A slash and or are compared together for two complete timing alternatives with explicit years. Each source is compared with the preceding checked date. Different wording in documents from the same day is shown separately, without assigning an order within that day. No comparison is made against a preceding date with different timing expressions. Status is set by founder review of the original filings.
| Document | Date | Event retained | Exact company wording | Review | Source |
|---|---|---|---|---|---|
| SEC Form 10-Q | Initial entry within checked sources: “in the second half of 2026” | We expect to report topline results from RISE 3 in the second half of 2026. | Checked by founder | SEC original | |
| SEC Exhibit 99.1 | Statement retained: “for 2H 2026” | Topline results from the Phase 2/3 RISE3 trial in focal epilepsy remain on track for 2H 2026. | Checked by founder | SEC original | |
| Company press release | Statement retained: “2H 2026” | with RISE3 trial topline results expected in 2H 2026. | Checked by founder | Company original | |
| SEC Exhibit 99.1 | Statement retained: “2H 2026” | with RISE3 trial topline results expected in 2H 2026. | Checked by founder | SEC original | |
| SEC Form 8-K | Statement retained: “for the second half of 2026” | topline data readout remains on timeline for the second half of 2026 | Checked by founder | SEC original | |
| SEC Form 8-K | Statement retained: “for the second half of 2026” | Dosing continues in BHV7000-303 and topline data remain on track for the second half of 2026. | Checked by founder | SEC original | |
| SEC Form 8-K | FDA partial clinical hold letter: | Context disclosed | partial clinical hold letter on September 4, 2026; new patient enrollment only; Dosing continues; topline data remain on track; second half of 2026 Item 8.01: paragraph beginning Thus, FDA and paragraph beginning BHV7000-303, one of two pivotal studies | Checked by founder | SEC original |
Sources
- SEC Form 10-Q — filed 2026-05-04
- SEC Exhibit 99.1 — filed 2026-08-10
- Company press release — company release 2026-08-26
- SEC Exhibit 99.1 — filed 2026-08-26
- SEC Form 8-K — filed 2026-09-10
- SEC Form 8-K — filed 2026-09-10
- Company release — 2026-08-26
- Company release — 2026-10-08
- Company press release listing — checked 2026-10-09
- Scope: Biohaven sponsor-submitted ClinicalTrials.gov record — 2026-08-13
- Context: SEC Form 8-K — filed 2026-09-10 · Item 8.01: paragraph beginning Thus, FDA and paragraph beginning BHV7000-303, one of two pivotal studies
Last checked: . Compared by hand with the original filings by Jiwoo Seong (Woo).
Corrections
| Date | What changed | Why | Evidence |
|---|---|---|---|
| Added source-context excerpts from 2026-09-10 SEC Form 8-K. | Founder-requested context retained from the checked original filing. | https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm | |
| Added previously omitted 2026-09-10 SEC Form 8-K timing source. | Selected-source supplement following founder review; prior rows retained. | https://www.sec.gov/Archives/edgar/data/1935979/000193597926000077/bhvn-20260904.htm |
: Display rule corrected — equivalent timing phrases (e.g., 'H2 2026' / 'second half of 2026') are now shown as Statement retained. Source quotes and status unchanged.
A correction is added here with its date, what changed, why, and the evidence. The earlier version is not deleted. Report an error: hello@orionbiotechai.com. If you want your name shown with the correction, include it; otherwise no name is shown.